Follow the 삼성바이오로직스 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares trade on the KR market, under the supervision of DART (FSS). Operating in the Health Care sector, 삼성바이오로직스 has logged 119 reports. Market capitalisation: €69,899.3bn. The latest transaction was disclosed on 20 May 2026 (Purchase). Among the most active insiders: 이재선. All data is accessible without an account.
117
Insider Decl.
n/a
Thresholds
n/a
36 ops.
Buy Volume
n/a
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 삼성바이오로직스 Strong Buy (bullish), based on 25 analysts. Average price target: ₩1,967,520.
Fundamental score
Ranked 9,525 of 29,113 companies
60.2
score / 100
Value
36
Quality
84
FCF yld1.1%
Earn yld2.6%
EV/EBITDA25.5x
ROE19%
Gross mgn55%
Net mgn39%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.